Show simple item record

dc.contributor.authorColeman-Cowger, V.H.
dc.contributor.authorOga, E.A.
dc.contributor.authorPeters, E.N.
dc.date.accessioned2019-05-17T13:21:15Z
dc.date.available2019-05-17T13:21:15Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85048575297&doi=10.1136%2fbmjopen-2017-020248&partnerID=40&md5=c688bd40198d54310f3e922358d7f235
dc.identifier.urihttp://hdl.handle.net/10713/9171
dc.description.abstractIntroduction Prescription-drug use in the USA has increased by more than 60% in the last three decades. Prevalence of prescription-drug use among pregnant women is currently estimated around 50%. Prevalence of illicit drug use in the USA is 14.6% among pregnant adolescents, 8.6% among pregnant young adults and 3.2% among pregnant adults. The first step in identifying problematic drug use during pregnancy is screening; however, no specific substance-use screener has been universally recommended for use with pregnant women to identify illicit or prescription-drug use. This study compares and validates three existing substance-use screeners for pregnancy - 4 P's Plus, National Institute on Drug Abuse (NIDA) Quick Screen/Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) and the Substance Use Risk Profile-Pregnancy (SURP-P) scale. Methods and analysis This is a cross-sectional study designed to evaluate the sensitivity, specificity and usability of existing substance-use screeners. Recruitment occurs at two obstetrics clinics in Baltimore, Maryland, USA. We are recruiting 500 participants to complete a demographic questionnaire, NIDA Quick Screen/ASSIST, 4 P's Plus and SURP-P (ordered randomly) during their regularly scheduled prenatal appointment, then again 1 week later by telephone. Participants consent to multidrug urine testing, hair drug testing and allowing access to prescription drug and birth outcome data from electronic medical records. For each screener, reliability and validity will be assessed. Test-retest reliability analysis will be conducted by examining the results of repeated screener administrations within 1 week of original screener administrations for consistency via correlation analysis. Furthermore, we will assess if there are differences in the validity of each screener by age, race and trimester. Ethics and dissemination This study is approved by the Institutional Review Board of the University of Maryland (HP-00072042), Baltimore, and Battelle Memorial Institute (0619-100106433). All participants are required to give their informed consent prior to any study procedure. Copyright Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.en_US
dc.description.sponsorshipFunding Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number R01DA041328.en_US
dc.description.urihttps://dx.doi.org/10.1136/bmjopen-2017-020248en_US
dc.language.isoen_USen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.ispartofBMJ Open
dc.subject4p's plusen_US
dc.subjectbiochemical verificationen_US
dc.subjectnida quick screen/assisten_US
dc.subjectpregnancyen_US
dc.subjectsubstance use screeningen_US
dc.subjectsurp-pen_US
dc.titleComparison and validation of screening tools for substance use in pregnancy: A cross-sectional study conducted in Maryland prenatal clinicsen_US
dc.typeArticleen_US
dc.identifier.doi10.1136/bmjopen-2017-020248
dc.identifier.pmid29455170


This item appears in the following Collection(s)

Show simple item record